Fisher & Paykel HealthcareASX:FPH +3.44%86 OCF Margin % is 34.56% as of Mar. 2026, which is 39% above its 10-year median of 24.84. GuruFocus rates ASX:FPH with a GF Score™ of 86/100 and a GF Value™ of A$36.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 91.17% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's OCF Margin % or its related term are showing as below:
ASX:FPH'
s OCF Margin % Range Over the Past 10 Years
Min: 14.99 Med: 24.84 Max: 42.85
Current: 28.52
During the past 13 years, the highest OCF Margin % of Fisher & Paykel Healthcare was 42.85%. The lowest was 14.99%. And the median was 24.84%.
ASX:FPH's OCF Margin % is ranked better than 91.17% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs ASX:FPH: 28.52
Fisher & Paykel Healthcare OCF Margin % Related Terms
Fisher & Paykel Healthcare OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a OCF Margin % of 34.56% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fisher & Paykel Healthcare and its competitors. This is 39% above median its historical median of 24.84. Over the past decade, Fisher & Paykel Healthcare's OCF Margin % has ranged from 14.99 to 42.85. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #72 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 8.8%.
Is Fisher & Paykel Healthcare's OCF Margin % too high?
Fisher & Paykel Healthcare's current OCF Margin % of 34.56% is 39% above median its 10-year median of 24.84. Over the past 10 years, this metric has ranged from a low of 14.99 to a high of 42.85. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Fisher & Paykel Healthcare's value of 34.56% is 489.8% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #72 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #72 out of 815 companies for OCF Margin %. This places Fisher & Paykel Healthcare in the top 9% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.86. Fisher & Paykel Healthcare's value of 34.56% is 489.8% above this benchmark. Historically, Fisher & Paykel Healthcare's own OCF Margin % has ranged from 14.99 to 42.85 over the past decade. While the company's 10-year median is 24.84 vs. the industry median of 5.86, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current OCF Margin % of 34.56% is 489.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current OCF Margin % is 34.56%, which is 39% above median its own 10-year median of 24.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.31, compared to a current price of A$31.53 — trading 13.2% below its estimated fair value. The current OCF Margin % is 34.56%, which is 39% above median its 10-year median of 24.84 and 489.8% above the Medical Devices & Instruments industry median of 5.86. Fisher & Paykel Healthcare's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current OCF Margin % is 34.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$31.53 is trading 13.2% below its estimated GF Value™ of A$36.31.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
OCF Margin %: 34.56% (39% above median its 10-year median of 24.84)
GF Value™: A$36.31 vs. price of A$31.53 (13.2% below fair value)
Industry Position: 489.8% above the Medical Devices & Instruments median (#72 of 815)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
86GF Score
Get the complete analysis for ASX:FPH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
